Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

Cancer Research

Volumn 66, Issue 21, 2006, Pages 10269-10273

  Zakikhani, Mahvash ^a   Dowling, Ryan ^a   Fantus, I George ^b   Sonenberg, Nahum ^a   Pollak, Michael ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; GROWTH INHIBITOR; INSULIN SENSITIZING AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; METFORMIN; S6 KINASE; SMALL INTERFERING RNA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIUM CELL; GLUCONEOGENESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL;

ADENYLATE KINASE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INSULIN; METFORMIN; PROTEIN BIOSYNTHESIS; RNA, SMALL INTERFERING;

EID: 33751284806     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1500     Document Type: Article

References (20)

1. Witters LA. The blooming of the French lilac. J Clin Invest 2001;108:1105-7.
2. Holland W, Morrison T, Chang Y, et al. Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol 2004;67:2081-91.
3. Shaw RJ, Lamia KA, Vasquez D, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005;310:1642-6.
4. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.
5. Hemmmki A, Markie D, Tomlinson I, et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998;391:184-7.
6. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000;119:1447-53.
7. Kahn BB, Alquier T, Carling D, Hardie DG. AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
8. Evans JM, Donnelly LA, Emslie-Smith AM, et al. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005;330:1304-5.
9. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29:254-8.
10. Shaw RJ, Kosmatka M, Bardeesy N, et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A 2004;101:3329-35.
11. Stapleton D, Mitchelhill KI, Gao G, et al. Mammalian AMP-activated protein kinase subfamily. J Biol Chem 1996;271:611-4.
12. Kritchevsky D, Klurfeld DM. Influence of caloric intake on experimental carcinogenesis: a review. Adv Exp Med Biol 1986;206:55-68.
13. Hursting SD, Lavigne JA, Berrigan D, et al. Diet-gene interactions in p53-deficient mice: insulin-like growth factor-1 as a mechanistic target. J Nutr 2004;134:2482-68.
14. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004;4:505-18.
15. Shaw RJ, Bardeesy N, Manning BD, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004;6:91-9.
16. Jishage K, Nezu J, Kawase Y, et al. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci U S A 2002;99:8903-8.
17. Pandini G, Frasca F, Mineo R, et al. Insulin/insulin-like growth factor-1 hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002;277:39684-95.
18. Sachdev D, Singh R, Fujita-Yamaguchi Y, et al. Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: implications for anti-insulin-like growth factor therapy in breast cancer. Cancer Res 2006;66:2391-402.
19. Goodwin PJ, Ennis M, Pritchard KI, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
20. Pollak M, Chapman J, Shepherd L, et al. Insulin resistance, estimated by serum c-peptide level, is associated with reduced event-free survival for postmenopausal women in the NCIC MA14 adjuvant breast cancer trial. J Clin Oncol 2006;24:524 (June 20 supplement).